Back to Search Start Over

Relative effect of hypertriglyceridemia on non-HDLC and apolipoprotein B as cardiovascular disease risk markers.

Authors :
Sun, Cathy J.
Brisson, Diane
Gaudet, Daniel
Ooi, Teik C.
Source :
Journal of Clinical Lipidology; Nov2020, Vol. 14 Issue 6, p825-836, 12p
Publication Year :
2020

Abstract

Non-high density lipoprotein cholesterol (non-HDLC) represents the cholesterol in triglyceride-rich lipoproteins (TRL) and low-density lipoproteins (LDL). Apolipoprotein B (apoB) reflects the number of TRL and LDL particles. In hypertriglyceridemia (HTG), there is triglyceride (TG) enrichment of TRLs, and also a substantial increase of cholesterol in larger TRLs that considerably augments the non-HDLC value. Therefore, in HTG, non-HDLC could increase disproportionately with respect to apoB. We aimed to compare the relative effect of the full range of mild, moderate, and severe HTG on the status of non-HDLC and apoB as cardiovascular disease (CVD) risk markers. Analysis of lipid profile data from 4347 patients in a Lipid Clinic cohort with baseline fasting lipid profiles documented prior to starting lipid-lowering medications. The correlation between non-HDLC and apoB was assessed in intervals of increasing TG. Non-HDLC and apoB were analyzed at each TG level using comparative CVD risk equivalent categories and assessed for divergence and discordance. With increasing TG levels: (1) the correlation between non-HDLC and apoB diminished progressively, (2) non-HDLC levels increased continuously, whereas apoB levels plateaued after an initial increase up to TG of ~ 4.0-5.0 mmol/L (~354-443 mg/dL), (3) there was divergence in the stratification of non-HDLC and apoB into CVD risk equivalent categories. Non-HDLC and apoB should not be viewed as interchangeable CVD risk markers in the presence of severe HTG. This has never been tested. With increasing HTG severity, discordance between non-HDLC and apoB can cause clinically important divergence in CVD risk categorization. • As TG increases, the correlation between non-HDLC and apoB decreases progressively. • In HTG, discordant non-HDLC and apoB causes divergence in CVD risk categorization. • Non-HDLC and apoB should not be viewed as interchangeable CVD risk markers in HTG. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
19332874
Volume :
14
Issue :
6
Database :
Supplemental Index
Journal :
Journal of Clinical Lipidology
Publication Type :
Academic Journal
Accession number :
147504289
Full Text :
https://doi.org/10.1016/j.jacl.2020.09.006